The DESCAR-T registry has been created at the request of the French Health Authorities to collect data on the efficacy and safety at both short- and long-term of all CAR-T cell therapies marketed in France.
Some cancers are refractory to CAR T-cells or relapse after some time. The project led by Dr. Roberta Di Blasi at Saint-Louis Hospital aims to describe the profile of patients who are refractory or relapse after CAR-T. This analysis also describes the relapses themselves (especially the time between CAR-T injection and relapse), the treatment offered after these relapse as well as the outcome of patients.
This research aims to better understand which patients are more susceptible to relapse after CAR T-cells in order to be able to offer the best therapeutic option for each person. This analysis will also provide some initial insights into the best treatment for patients relapsing after CAR-T.
The analyses for this project are made by the LYSARC, using data from patients treated for B-cell lymphoma included in the registry before July 2021.
To the patients that received CAR-T, if you would like more information about the treatment of your data in the DESCAR-T Registry, you can contact the doctor at your centre of care for your CAR-T treatment or make a request at dpo@lysarc.org. You can find more details your rights regarding your data in the section “I am participating or have participated in a clinical trial“, or in the Patient Information Leaflet you received at the time of your inclusion in the registry.